ABBV vs MS: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Morgan Stanley — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-22.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Morgan Stanley · Financial Services
$189.30
-30.5% upside to fair value
Grade C
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(+4.5%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
MS |
| Current Price |
$208.05 |
$189.30 |
| Fair Value Estimate |
$217.50 |
$131.49 |
| Upside to Fair Value |
+4.5%
|
-30.5%
|
| Market Cap |
$367.9B |
$300.6B |
| Forward P/E |
14.9x
|
16.4x
|
| EV / EBITDA |
16.7x
|
24.4x
|
| Price / Sales |
6.1x
|
2.5x
|
| Price / FCF |
20.9x
|
-16.8x
|
| Revenue Growth YoY |
+8.6%
|
+18.8%
|
| Gross Margin |
83.7%
|
58.0%
|
| Operating Margin |
34.7%
|
19.5%
|
| Return on Equity |
-129.24%
|
16.7%
|
| Dividend Yield |
3.2% |
0% |
| FCF Yield |
4.78%
|
—
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Morgan Stanley is a leading global financial services firm operating in Institutional Securities, Wealth Management, and Investment Management. The company benefits from a durable competitive moat supported by its systemically important status, diversified revenue streams, and strong management with a 36-year veteran CEO. Despite solid fundamentals including 14.2% revenue growth in 2025 and 16.7%…
Accumulation Zones
| Metric |
ABBV |
MS |
| Zone Low |
$163.13 |
$98.62 |
| Zone High |
$184.88 |
$111.77 |
| In Buy Zone? |
No
|
No
|